• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases
      • All News Releases
      • All Public Company
      • English-only


      • News Releases Overview
      • Multimedia Gallery
      • All Multimedia
      • All Photos
      • All Videos


      • Multimedia Gallery Overview
      • Trending Topics
      • All Trending Topics


  • Business & Money
      • Auto & Transportation
      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation


      • Auto & Transportation Overview
      • Business Technology
      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors


      • Business Technology Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television


      • Entertain­ment & Media Overview
      • Financial Services & Investing
      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Stock Offering
      • Stock Split
      • Venture Capital


      • Financial Services & Investing Overview
      • General Business
      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News


      • General Business Overview
  • Science & Tech
      • Consumer Technology
      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications


      • Consumer Technology Overview
      • Energy & Natural Resources
      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities


      • Energy & Natural Resources Overview
      • Environ­ment
      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters


      • Environ­ment Overview
      • Heavy Industry & Manufacturing
      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco


      • Heavy Industry & Manufacturing Overview
      • Telecomm­unications
      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications


      • Telecomm­unications Overview
  • Lifestyle & Health
      • Consumer Products & Retail
      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys


      • Consumer Products & Retail Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television


      • Entertain­ment & Media Overview
      • Health
      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine


      • Health Overview
      • Sports
      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories


      • Sports Overview
      • Travel
      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry


      • Travel Overview
  • Policy & Public Interest
      • Policy & Public Interest
      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy


      • Policy & Public Interest Overview
  • People & Culture
      • People & Culture
      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women


      • People & Culture Overview
      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO

      Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Policy & Public Interest
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • People & Culture
    • People & Culture
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Muscular Dystrophy Association announces 34 new research grants totaling $9.9 million

Muscular Dystrophy Association logo. (PRNewsFoto/Muscular Dystrophy Association)

News provided by

Muscular Dystrophy Association

Aug 23, 2018, 09:00 ET

Share this article


NEW YORK, Aug. 23, 2018 /PRNewswire/ -- The Muscular Dystrophy Association today announced the award of 34 new grants totaling more than $9.9 million for its summer round of funding. These new grants represent a continued commitment by MDA to fund groundbreaking research that will accelerate treatments and cures for the more than 40 diseases in its program.

"This latest round of grants is impressive in terms of total funding, number of grants awarded and the diverse impact these grants will have in furthering neuromuscular disease research," said MDA President & CEO Lynn O'Connor Vos. "With each grant cycle we are getting closer to unlocking the mysteries of so many of these neuromuscular diseases and identifying therapeutic targets that will lead to life-changing treatments, which is very exciting."

Of note in this latest round of funding are two grants awarded to set up clinical research networks for facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD), respectively. Additionally, a research infrastructure grant was awarded to fund the development of computational tools that can integrate and analyze complex amyotrophic lateral sclerosis (ALS) data sets.

This latest round of funding also includes 24 research grants awarded to established, independent investigators; five development grants awarded to investigators at the beginning of their careers and who are on the brink of becoming independent investigators; one clinical trial travel grant to help alleviate the financial burden on individuals and families traveling to participate in clinical research; and one clinical research training scholarship to a physician in the early stage of their medical career who is interested in pursuing a career in clinical neuromuscular research.

For more than six decades, MDA has funded basic, translational and clinical research as it works to unlock the mechanisms of neuromuscular disease and enable scientists and clinicians to develop safe and effective therapies capable of changing lives. The power of MDA's research program lies in its big-picture approach that leverages insights and information resulting from research in one disease area to inform and advance discoveries and breakthroughs in others. Many of the new awards were made to leading scientists who are conducting innovative research targeted to make an impact across multiple diseases in MDA's program.

The latest round of research grants was approved by MDA's Board of Directors following careful deliberations and analysis by MDA's Research Advisory Committee, through which approximately 50 leading clinicians and scientists in volunteer roles oversee the peer-review process.

Vital research and services dollars come from generous MDA partners and supporters who organize, and donate to, community fundraising programs including the International Association of Fire Fighters (IAFF), CITGO Petroleum Corporation, Harley-Davidson Motor Co., Acosta, Albertsons Companies, Casey's General Stores, Circle K, The Kroger Company, National Association of Letter Carriers and Dutch Bros. Coffee.

"This latest round of grants is a testament to the advances in technology and drug discovery that have taken place in the last few years," said MDA Senior Vice President and Scientific Director Grace Pavlath, Ph.D. "The opportunity to fund groundbreaking research has never been greater, and MDA remains committed to achieving our ultimate goal of providing treatments and cures for our community."

MDA is currently funding 177 different research projects around the world with a combined investment of $47.3 million.

Notable awards from the latest grant period:

Melissa Spencer, Ph.D., professor of Neurology at the University of California at Los Angeles, was awarded an MDA Research Grant to develop nanoparticles for the treatment of neuromuscular disorders, including Duchenne muscular dystrophy (DMD). This technique is an alternative approach to the delivery of therapies based on gene editing, gene replacement and gene silencing. Nanoparticle-based delivery has the potential to be more accurate and effective than the adeno-associated virus (AAV) method currently in use in gene therapy trials today.

Francis Sverdrup, Ph.D., associate professor of Biochemistry and Molecular Biology at St. Louis University, was awarded an MDA Research Grant to study drugs targeting DUX4 expression in FSHD. DUX4 protein in skeletal muscle is considered the leading cause of muscle degeneration in FSHD. Sverdrup's aim will be to continue work on recently identified compounds to find the most effective way to suppress DUX4, which may one day lead to a treatment for FSHD.

Carlo Rinaldi, Ph.D., associate professor and clinician scientist at the University of Oxford in England, was awarded an MDA Development Grant to study how variants in the gene of the androgen receptor (AR) protein cause spinal-bulbar muscular atrophy (SBMA) and investigate whether a novel antisense oligonucleotide therapy approach can target these toxic variants. The results of the study will provide a better understanding of SBMA disease mechanisms, as well as develop a new therapy potentially capable of treating the disease.

Ludo Van Den Bosch, Ph.D., principal investigator at VIB in Leuven, Belgium, was awarded an MDA Research Grant to study the role of histone deacetylase inhibitors in mouse models as a potential therapeutic approach for ALS. In ALS patients, the motor axon is the most vulnerable compartment determining survival of the nerve cell and it is thought that by inhibiting histone deacetylse 6 (HDAC6), the motor axon can be preserved. Previous MDA-supported work by Dr. Van Den Bosch has highlighted HDAC6 as a potential therapy for Charcot-Marie-Tooth disease (CMT), currently under development by industry.

Francesco Muntoni, M.D., chair of Pediatric Neurology in the ICH Developmental Neurosciences Programme at the UCL GOS Institute of Child Health in London, England, was awarded an MDA Research Grant to identify novel gene mutations in congenital muscular dystrophy (CMD) and in congenital myopathy (CMY) using advanced genetic techniques. Muntoni's research will aim to establish the gene-causing mutation in individuals with these conditions whose initial gene sequencing was not conclusive.

Samya Chakravorty, Ph.D., postdoctoral research fellow at Emory University, was awarded an MDA Development Grant to study the functional resolution of a subset of unsolved cases from MDA's LGMD genetic testing platform. The goal is to investigate these gene variants to see if these cases are the result of multi-gene pathogenicity — whether instead of one genetic defect, patients have multiple defects that are causing their symptoms.

Michio Hirano, M.D., professor of Neurology at Columbia University Irving Medical Center, was awarded an MDA Research Grant to conduct an open-label expanded access trial of deoxynucleoside therapy for thymidine kinase 2 (TK2) deficiency, a type of mitochondrial DNA depletion syndrome (MDS). To date, 15 individuals have been treated with this therapy Hirano developed via compassionate-use mechanisms. With this current funding, a uniform prospective study on the safety and efficacy of this treatment in TK2 patients will be conducted, and the results will inform the design of the pivotal clinical trial necessary to obtain FDA approval. 

Investing in clinical research infrastructure

In this latest round of grants, MDA has strategically committed funding to invest in clinical research tools and infrastructure that are crucial to better understanding disease pathways and accelerating treatments in ALS, FSHD and LGMD.

MDA awarded two clinical research network grants for FSHD and LGMD. Each grant will support a network of MDA Care Centers with expertise in each disease's research and clinical care and is targeted to facilitate the development of the tools and infrastructure needed to conduct clinical trials and accelerate treatments. Jeffrey Statland, Ph.D., principal investigator at the University of Kansas Medical School, will head up the FSHD network and Nicholas Johnson, Ph.D., associate professor of Neurology at Virginia Commonwealth University, will lead the LGMD network.  

Additionally, MDA awarded a Research Infrastructure Grant to Jeffrey Rothstein, M.D., Ph.D., at Johns Hopkins University School of Medicine to fund the development of new data analytics approaches for the Answer ALS research project. These analytics tools will support the integration and analysis of more than 20 trillion data points generated by Answer ALS, with the goal of enhancing understanding of ALS disease mechanisms and advancing the discovery of targets for effective therapy.

2018 summer grants materials

  • MDA announces 34 new research grants totaling $9.9 million, by Grace Pavlath, Ph.D., MDA Senior Vice President & Scientific Director
  • MDA Grants at a Glance

MDA has funded more than $1 billion in neuromuscular disease research since 1950. In just the last three years, four drugs have been approved by the FDA that can trace their origins directly to MDA funding. These successes illustrate the vibrancy of MDA's research program and the welcoming of a new era in treating neuromuscular diseases.

About the Muscular Dystrophy Association

MDA is leading the fight to free individuals — and the families who love them — from the harm of muscular dystrophy, ALS and related muscle-debilitating diseases that take away physical strength, independence and life. We use our collective strength to help kids and adults live longer and grow stronger by finding research breakthroughs across diseases; caring for individuals from day one; and empowering families with services and support in hometowns across America. Learn how you can fund cures, find care and champion the cause at mda.org.

SOURCE Muscular Dystrophy Association

Related Links

http://www.mdausa.org

Modal title

Also from this source

MDA Names Kristine Welker as Chief of Staff...


John Howell Appointed to the Muscular Dystrophy Association's...

Explore

More news releases in similar topics

  • Health Care & Hospitals
  • Medical Pharmaceuticals
  • Not For Profit

    Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

    Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

    About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement

    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom

    My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision


Products


About


My Services
  • All News Releases
  • Online Member Center
  • ProfNet℠
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2021 Cision US Inc.